FGI-103

FGI-103 is an experimental antiviral drug that is being developed for the treatment of viral infections. It is a small molecule that has been shown to have broad-spectrum antiviral activity against a number of different viruses, including influenza, SARS-CoV, MERS-CoV, and Ebola virus.

Mechanism of Action

FGI-103 works by inhibiting the replication of viruses. It does this by interfering with the function of the viral RNA polymerase, a key enzyme that viruses use to copy their genetic material. By blocking the activity of this enzyme, FGI-103 prevents the virus from replicating and spreading within the body.

Clinical Trials

FGI-103 has been tested in a number of preclinical studies and has shown promising results. In animal models of influenza, SARS-CoV, MERS-CoV, and Ebola virus infection, treatment with FGI-103 resulted in a significant reduction in viral load and improved survival.

Clinical trials in humans are currently underway to further evaluate the safety and efficacy of FGI-103.

Potential Applications

If proven safe and effective in clinical trials, FGI-103 could potentially be used to treat a wide range of viral infections. This could include emerging viral diseases, such as COVID-19, as well as more established infections, such as influenza.

See Also

• Antiviral drug
• Influenza
• SARS-CoV
• MERS-CoV
• Ebola virus
• Clinical trial
• Viral replication

• 
  FGI-103